1.11
+2.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Codexis
From its filings with the US Securities and Exchange Commission
Codexis is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CDXS. The SEC classifies its business as industrial organic chemicals. In the fiscal year to 31 December 2025, it reported revenue of $70.4m and a net loss of $44.0m. At that date it held total assets of $147.8m and shareholders' equity of $50.5m.
We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by using our proprietary CodeEvolver® directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions. They can be precisely engineered and optimized for specific functions, and to have particular characteristics, such as an ability to survive environments in which natural enzymes cannot, or to perform (bio)chemical transformations that are different than those for which they naturally evolved. We employ our technology and expertise to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key areas: our ECO synthesis manufacturing platform and our small molecule pharma biocatalysis business.
Our ECO Synthesis® manufacturing platform is comprised of enzymatic tools and processes that are designed to enable large-scale manufacture of RNA interference (“RNAi”) therapeutics. We use the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics in production processes that deliver improvements, including purity, yield, and manufacturing efficiency.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 22 Apr 2010
- Employees
- 146
- Website
- codexis.com ↗
- Head office
- 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063
- Incorporated in
- DE
- Classification
- Industrial Organic Chemicals
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Stephen DillyChairman of the Board, President, Chief Executive Officer, since 2020$3.5m
- Ms. Georgia ErbezChief Financial Officer$931,593
- Mr. Kevin NorrettChief Operating Officer$1.5m
- Dr. Alison MooreExecutive Vice President, Chief Technical Officer, since 2020$1.1m
- Mr. David SmithLead Independent Director$214,835
- Ms. Cynthia CollinsIndependent Director
- Dr. Raymond De VreIndependent Director$207,473
- Dr. Esther MartinboroughIndependent Director$175,000
- Ms. H. Stewart ParkerIndependent Director$187,280
- Mr. Christos RichardsIndependent Director
- Dr. Rahul SinghviIndependent Director$205,000
- Mr. Dennis WolfIndependent Director$190,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 61
- Social
- 99
- Governance
- 68
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Codexis Inc has a strong and experienced management team, enabling effective decision-making and business strategy implementation. The company possesses cutting-edge biotechnology expertise, allowing it to develop innovative and high-quality products. Codexis also has a strong intellectual property portfolio, which provides a competitive advantage in the industry.
Weaknesses
- One of the weaknesses of Codexis Inc is its high dependence on a limited number of key customers. This reliance creates vulnerability in case of any disruptions or changes in customers' preferences. The company also faces challenges in effectively managing its research and development costs, as developing new products requires substantial investments.
Opportunities
- Codexis Inc has significant opportunities for growth in the expanding biotechnology and pharmaceutical markets. The increasing demand for sustainable and environmentally friendly solutions presents a favorable market for Codexis' biocatalysis technology. The company can also explore strategic partnerships and collaborations to expand its market reach and access new customers.
Threats
- One of the potential threats for Codexis Inc is intense competition in the biotechnology industry. Rival companies with similar technologies and product offerings may limit the market share of Codexis. The company also faces regulatory risks, as changes in government regulations and policies related to biotechnology can impact its operations. Additionally, macroeconomic factors such as economic downturns can affect customer spending and demand for Codexis' products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.